Catalent (CTLT) Reports Q1 Earnings: What Key Metrics Have to Say
Catalent (CTLT) reported $982 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 3.9%. EPS of -$0.10 for the same period compares to $0.34 a year ago.
The reported revenue represents a surprise of +5.23% over the Zacks Consensus Estimate of $933.2 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +23.08%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Catalent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Organic Revenue Growth: -8% versus -10.3% estimated by two analysts on average.
Geographic Revenues- United States: $645 million compared to the $627.43 million average estimate based on two analysts.
Elimination of revenue: -$25 million versus -$24.43 million estimated by two analysts on average.
Revenue- International Other: $88 million versus the two-analyst average estimate of $70 million.
Revenue- Europe: $274 million versus $275.56 million estimated by two analysts on average.
Revenue- Biologics: $447 million compared to the $420.93 million average estimate based on four analysts.
Revenue- Pharma and Consumer Health: $535 million versus the four-analyst average estimate of $498.21 million.
Revenue- Pharma and Consumer Health- Manufacturing & commercial product supply: $335 million versus the two-analyst average estimate of $314.22 million.
Revenue- Pharma and Consumer Health- Development services & clinical supply: $200 million versus the two-analyst average estimate of $210.93 million.
Revenue- Manufacturing & commercial product supply Total: $616 million versus the two-analyst average estimate of $404.15 million.
Revenue- Development services & clinical supply Total: $366 million versus $547.08 million estimated by two analysts on average.
Revenue- Biologics- Manufacturing & commercial product supply: $281 million versus the two-analyst average estimate of $89.93 million.
View all Key Company Metrics for Catalent here>>>
Shares of Catalent have returned -12.1% over the past month versus the Zacks S&P 500 composite's +4.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalent, Inc. (CTLT) : Free Stock Analysis Report
